This content is only available to 2025 ASCRS Annual Meeting physician registrants
To log in, click the teal "Login" button in the upper right-hand corner of this page. If you are logged in but still do not have access, please check your 2025 Annual Meeting registration.
In recent years, MIGS has become the treatment of choice for early stage of glaucoma. However, problems with current MIGS include anterior chamber hemorrhage, transient elevation of intraocular pressures, and re-adhesion. We examined whether the TRABECTOR®, which is a Trabecular Meshwork Cutter and has already been approved in Japan, could be a new MIGS device that could solve these problems.